749 / 1631
BCL-2 Inhibition
Bcl-2 highly expressed in FL
GDC-0199 oral active Bcl-2 inhibitor
Phase I dose escalation
200-900 mg cohorts
N=44 with NHL
FL =11 (26%)
Nausea (34%), diarrhoea (25%), fatigue (21%)
Tumour lysis in 1 patient each with DLBCL and
MCL
3/11 responses in FL
R2PD not yet established
GDC-0199